Gensight Biologics S.a annual return on assets (roa)
2021
2022
2023
2024
2025
Gensight Biologics S.a Return on Assets (ROA) Growth & History (SIGHT)
Gensight Biologics S.a's return on assets (roa) was −126.61% for fiscal 2025.
View full Gensight Biologics S.a company overviewGensight Biologics S.a annual return on assets (roa) history
| Fiscal year | Period ended | Return on assets (ROA) | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −126.61% | +14.18 pp |
| 2024 | 2024-12-31 | −140.80% | +8.72 pp |
| 2023 | 2023-12-31 | −149.52% | −82.62 pp |
| 2022 | 2022-12-31 | −66.90% | −11.87 pp |
| 2021 | 2021-12-31 | −55.03% | — |
Gensight Biologics S.a return on assets (roa) trends
Between the periods ended 2021-12-31 and 2025-12-31, Gensight Biologics S.a's return on assets (roa) decreased from −55.03% to −126.61%, a change of −71.59 percentage points.
About the metric
What return on assets means
Return on assets measures profit relative to the assets used to generate it. It can help compare operating efficiency over time, although normal ROA differs substantially between asset-light and asset-intensive industries.
Calculation and source
How return on assets is calculated
TickerStat calculates annual ROA as reported net income divided by average total assets. Quarterly observations use trailing-12-month net income and average assets over the corresponding one-year period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Gensight Biologics S.a source filings ↗Community posts
GenSight advances LUMEVOQ manufacturing transfer to Catalent
GenSight ($SIGHT) said an engineering batch of GS010/LUMEVOQ at Catalent was produced as planned, with viral genome concentration meeting target specifications. Preparations have begun for a GMP-standard batch to supply special-access progr ...